ArticleJournal of clinical neurology (Seoul, Korea)2009
Muscle-specific receptor tyrosine kinase antibody positive myasthenia gravis current status.
Article in Journal of clinical neurology (Seoul, Korea), 2009. The graph could read no effect estimate from its abstract, so it casts no vote on the map. Cited by 18 papers.
What it found
Each row is one number read from the abstract, on the scale the paper reported it, with its interval. Left of the dashed line favours the treatment, right favours the comparator. Under each row is the sentence it came from. New to these charts? A ten-minute tutorial.
The abstract states no effect estimate the extractor could read, or names no intervention and outcome on the map, so this paper lights no cell and moves no belief. It is still indexed, cited and linked below.
The trial behind it
Trials whose registry record cites this paper, or whose number appears in the abstract. A trial that started after this paper was published is citing it as background, not reporting it.
Neither the registry nor the abstract names a trial number. If this is a trial report, that itself is worth knowing.
Who cites it
18 citing papers in PubMed, 78 citations in OpenAlex.
- Outcomes of myasthenia gravis patients admitted to the Intensive Care Unit: Experience from a tertiary care center in Saudi Arabia.PloS one · 2025Article
- A predictive nomogram for short-term outcomes of myasthenia gravis patients treated with low-dose rituximab.CNS neuroscience & therapeutics · 2024Article
- A clinical perspective on muscle specific kinase antibody positive myasthenia gravis.Frontiers in immunology · 2024Review
- Optimal time for the addition of non-corticosteroid immunosuppressants in myasthenia gravis: a single-center retrospective study in China.Frontiers in neurology · 2024Article
- Immunotherapies in MuSK-positive Myasthenia Gravis; an IgG4 antibody-mediated disease.Frontiers in immunology · 2023Review
- Spotlight on MuSK positive myasthenia gravis: clinical characteristics, treatment and outcomes.BMC neurology · 2022Article
- MuSK-Myasthenia Gravis Unmasked by Hydroxychloroquine.Case reports in medicine · 2022Article
- Clinical Features of Myasthenia Gravis With Antibodies to MuSK Based on Age at Onset: A Multicenter Retrospective Study in China.Frontiers in neurology · 2022Article
- Clinical features and outcomes of patients with myasthenia gravis.Neurosciences (Riyadh, Saudi Arabia) · 2019Article
- Circulating microRNA plasma profile in MuSK+ myasthenia gravis.Journal of neuroimmunology · 2018Article
- Muscle-Specific Tyrosine Kinase and Myasthenia Gravis Owing to Other Antibodies.Neurologic clinics · 2018Review
- Practical Anatomy of the Neuromuscular Junction in Health and Disease.Neurologic clinics · 2018Review
- Repetitive Nerve Stimulation in MuSK-Antibody-Positive Myasthenia Gravis.Journal of clinical neurology (Seoul, Korea) · 2017Article
- Anti-MuSK-positive myasthenia gravis diagnosed during pregnancy: new challenges for an old disease?BMJ case reports · 2015Article
- Treatment of MuSK-Associated Myasthenia Gravis.Current treatment options in neurology · 2014Article
- The role of muscle-specific tyrosine kinase (MuSK) and mystery of MuSK myasthenia gravis.Journal of anatomy · 2014Review
- Ocular myasthenia gravis: controversies and updates.Current neurology and neuroscience reports · 2014Article
- The association of systemic lupus erythematosus and myasthenia gravis: a series of 17 cases, with a special focus on hydroxychloroquine use and a review of the literature.Journal of neurology · 2012Review
Corrections and comments
PubMed lists nothing against this paper. Absence here is not a guarantee, only a check that was made.
Authors and funding
1 author at 1 institution in 1 country.
Funding
No grant is acknowledged in the PubMed record.
Abstract
Muscle-specific tyrosine-kinase-antibody-positive myasthenia gravis (MuSK-MG) has emerged as a distinct entity since 2001. This disease has been reported worldwide, but with varying rates among patients with generalized acetylcholine-receptor-antibody-negative MG. MuSK-MG was detected in approximately 37% of generalized acetylcholine receptor antibody-negative MG. MuSK-MG patients were predominantly female with more prominent facial and bulbar involvement and more frequent crises. Disease onset tended to be earlier. Patients tended to have a relatively poor edrophonium response but showed prominent decrement in the repetitive nerve stimulation test in the facial muscles. Patients were more likely to display poor tolerance of, or a lack of improvement with, anticholinesterase agents. Somewhat better response was observed with steroids and plasma exchange. Most were managed successfully with aggressive immunomodulatory therapies, although a higher proportion of MuSK-MG patients had a refractory course when compared with other forms of generalized MG. I present here an up-to-date overview on MuSK-MG based on our experience at the University of Alabama at Birmingham and the existing literature.
Indexed as
Identifiers
What OpenQuestion holds
Registered trials
Read under generation 80e0d062 · epoch 390. Bibliography from PubMed, PubMed Central and OpenAlex; grants from NIH RePORTER; trial links from ClinicalTrials.gov; estimates, votes and beliefs from the OpenQuestion graph.